Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Resistant Hypertension: An Overview
Author(s): Giacomo Buso , Claudia Agabiti-Rosei , Matteo Lemoli , et al Added: 1 year ago

Prevention & Chronic Conditions
Arterial Hypertension: Highlights from the European Society of Cardiology 2025 Congress
Author(s): Maria Lorenza Muiesan , Matteo Lemoli Added: 2 months ago

Prevention & Chronic Conditions
ESC 23: The PUSH-AHF Study
Author(s): Jozine ter Maaten Added: 2 years ago
ESC 2023 — Dr Jozine Ter Maaten (University Medical Centre Groningen, NL) joins us to outline the findings from the PUSH-AHF Study (NCT04606927). PUSH-AHF (University Medical Center Groningen) aimed to assess the effect of natriuresis-guided therapy in patients with acute heart failure to improve diagnostic response, decongestion and clinical outcomes. 310 patients with a primary diagnosis of… View more

Heart Failure
Jozine ter Maaten
Research Area(s) / Expertise:

Heart Failure

 Job title: Cardiologist
Dr Jozine ter Maaten is a cardiologist at the University Medical Center Groningen, specializing in acute heart failure. Her research focuses on understanding congestion and improving diuretic response and outcomes in patients with this condition. Dr ter Maaten completed her PhD on 'Diuretic response and renal biomarkers in heart failure' in 2016 and has since been actively involved in research… View more
Viewpoint on Arterial Hypertension
Author(s): Maria Lorenza Muiesan Added: 9 months ago

Prevention & Chronic Conditions
ACC 25 Late-Breaking Discussion: The ADVANCE-HTN Trial
Author(s): Harriette Van Spall , Luke Laffin Added: 9 months ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial… View more

Prevention & Chronic Conditions
ESC Congress 2025 Releases its Late-Breaking Scientific Programme
Added: 6 months ago Source:  ESC Congress 2025 Scientific Programme
ESC Congress 2025 has released twenty-eight late-breaking trials and science sessions to be presented in August 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Late-Breaking Clinical Science: Inflammation and Immune Biomarkers in Cardiovascular Risk PredictionFriday 29th August, 08:15am – 09:45am (CEST… View more

Cardiovascular Renal Metabolic

Demographic
THT 2025: The FASTR Trial
Author(s): James Udelson Added: 10 months ago
THT Conference 2025 - Positive safety and efficacy outcomes were found of the Reprieve decongestion management system (DMS; Reprieve Cardiovascular, Inc) for the treatment of acute decompensated heart failure (ADHF). Urinary sodium excretion was seen to be significantly higher in the Reprieve DMS arm than in the control arm, and there were fewer UTI infections in ADHF patients receiving the… View more

Heart Failure
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie
Author(s): Harriette Van Spall , Mark Petrie Added: 1 year ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of… View more

Demographic

Heart Failure
Maternal Cardiac Function in Pregnancies With Metabolic Disorders
Author(s): Deesha Patel , Makrina D Savvidou Added: 1 year ago

Imaging & Diagnostics

Prevention & Chronic Conditions